» Articles » PMID: 21038326

A Photoelectrochemical Immunosensor Based on Au-doped TiO2 Nanotube Arrays for the Detection of α-synuclein

Overview
Journal Chemistry
Specialty Chemistry
Date 2010 Nov 2
PMID 21038326
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

α-Synuclein (α-SYN) is a very important neuronal protein that is associated with Parkinson's disease. In this paper, we utilized Au-doped TiO(2) nanotube arrays to design a photoelectrochemical immunosensor for the detection of α-SYN. The highly ordered TiO(2) nanotubes were fabricated by using an electrochemical anodization technique on pure Ti foil. After that, a photoelectrochemical deposition method was exploited to modify the resulting nanotubes with Au nanoparticles, which have been demonstrated to facilitate the improvement of photocurrent responses. Moreover, the Au-doped TiO(2) nanotubes formed effective antibody immobilization arrays and immobilized primary antibodies (Ab(1)) with high stability and bioactivity to bind target α-SYN. The enhanced sensitivity was obtained by using {Ab(2)-Au-GOx} bioconjugates, which featured secondary antibody (Ab(2)) and glucose oxidase (GOx) labels linked to Au nanoparticles for signal amplification. The GOx enzyme immobilized on the prepared immunosensor could catalyze glucose in the detection solution to produce H(2)O(2), which acted as a sacrificial electron donor to scavenge the photogenerated holes in the valence band of TiO(2) nanotubes upon irradiation of the other side of the Ti foil and led to a prompt photocurrent. The photocurrents were proportional to the α-SYN concentrations, and the linear range of the developed immunosensor was from 50 pg  mL(-1) to 100 ng  mL(-1) with a detection limit of 34 pg  mL(-1). The proposed method showed high sensitivity, stability, reproducibility, and could become a promising technique for protein detection.

Citing Articles

Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.

Majumdar M, Badwaik H Curr Drug Targets. 2024; 25(15):987-1011.

PMID: 39313872 DOI: 10.2174/0113894501312703240826070530.


Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.

Tapia-Arellano A, Cabrera P, Cortes-Adasme E, Riveros A, Hassan N, Kogan M J Nanobiotechnology. 2024; 22(1):248.

PMID: 38741193 PMC: 11092257. DOI: 10.1186/s12951-024-02526-0.


Designing and Formulation of Nanocarriers for "Alzheimer's and Parkinson's" Early Detection and Therapy.

Abujamai J, Satar R, Ansari S CNS Neurol Disord Drug Targets. 2024; 23(10):1251-1262.

PMID: 38351689 DOI: 10.2174/0118715273297024240201055550.


Nanophytomedicines as Therapeutic Agents for Parkinson's Disease.

Burns J, Buck A, D Souza S, Dube A, Bardien S ACS Omega. 2023; 8(45):42045-42061.

PMID: 38024675 PMC: 10652730. DOI: 10.1021/acsomega.3c04862.


Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes.

Padilla-Godinez F, Ruiz-Ortega L, Guerra-Crespo M Cells. 2022; 11(21).

PMID: 36359841 PMC: 9657131. DOI: 10.3390/cells11213445.